Results for Ipilimumab and Nivolumab Following Autologous Stem Cell Transplant in Multiple Myeloma


Andrew L. Pecora, MD, President of the Physician Services Division and Chief Innovation Officer at Hackensack Meridian Health, discusses preliminary safety and efficacy data for combined checkpoint inhibition with ipilimumab (Yervoy) and nivolumab (Opdivo) as consolidation therapy following autologous stem cell transplant in patients with multiple myeloma and non-Hodkin lymphoma.

Related Videos
Expert on GVHD
Related Content